New #JITC short report: Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) bit.ly/3JOiwqc Matthew Frigault Dr Marcela Maus

Our 4th most downloaded article of 2021: Recent advances and discoveries in the mechanisms and functions of CAR T cells by RC Larson & Dr Marcela Maus go.nature.com/2Y8lcbL Harvard Medical School #NRCtop10of2021 #Immunotherapy

Decades of studying the immune system's response to a virus help #researchers discover new treatments and potential cures to deadly diseases. Learn how this team at Mass General Brigham is working to change medicine. nyti.ms/3JX7iie

Excited to share the latest work from my PhD! We performed the first CRISPR activation screen to identify genes that drive solid tumor resistance to T cell-mediated cytotoxicity. A thread 1/X nature.com/articles/s4146…

When a pediatric oncologist gives a plenary talk at #AACR2022, you see evidence of CAR-T cell success with improvement in coloring skills. So proud and grateful to our brave patients. Congrats to Majzner_Lab for an amazing talk. Sneha Ramakrishna Mackall Lab Michelle Monje🎗️

Mechanisms of CAR T-cell therapy + #immunotherapy being discussed today at #AACR22 by St. Baldrick's Foundation Stand Up To Cancer #PediatricCancer Dream Team Co-leader Dr. Crystal Mackall + Innovative Rsch Grant Recipient Dr Marcela Maus Mackall Lab Stanford Cancer Institute MassGeneral News abstractsonline.com/pp8/#!/10517/s…

Today #AACR22, don’t miss Nicholas Haradhvala presenting on single-cell analysis of cellular dynamics underlying clinical response to #CARTcell therapy in #collab work with Cathy Wu and Dr Marcela Maus labs (Talk #3575). Then, read more of the story @medrxiv: medrxiv.org/content/10.110…

Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by Dr Marcela Maus and colleagues nature.com/articles/s4158…

Critical findings from a study nature led by Dr Marcela Maus differentiating CAR T-cell efficacy against liquid versus solid tumors like #Glioblastoma ...INFg is the key! nature.com/articles/s4158…

Saw @Marcelamaus present this at #AACR2022 - really beautiful story! congrats.

✨ New today in nature! Dr. Dr Marcela Maus at Harvard Medical School and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway. go.nature.com/3xr4bfz

How do CAR-T cells kill tumor cells? - It depends… Exciting work nature by Dr Marcela Maus Rebecca Larson & colleagues on the role of IFNg signaling in CAR-T mediated killing. Congrats to the entire team! nature.com/articles/s4158…

Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC Cancer Cell cell.com/cancer-cell/fu…

Exciting new CAR design for AML from our lab! Now online Cancer Cell Mass General Cancer Center Mass General Brigham Innovation

.MassGeneral News researchers, led by ASGCT Board Member Dr Marcela Maus & Associate Member Mark Leick, developed a novel treatment strategy that has the potential to bring the benefits of #CART #celltherapy to patients with acute myeloid #leukemia (#AML). bit.ly/3kq9JPP

Not all people respond equally well to CAR-T cell therapy, a kind of immunotherapy that has dramatically improved blood cancer treatment. A new single-cell study by researchers at the Broad, MassGeneral News, and Dana-Farber could help reveal why. broad.io/carttherapy0912

A collaborative team at the Broad Institute describes distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma. 🥼 Dr Marcela Maus Gaddy Getz Mark Leick Katie Maurer Satyen Gohil Learn more: go.nature.com/3eQtbWc

High antigen density of BCMA: friend or foe to CAR T cells? jitc.bmj.com/content/10/9/e…

Today, NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators MGH Neurosurgery and Mass General Cancer Center! nej.md/3VnjUIq

Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the Mass General Cancer Center with Dr Marcela Maus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6011Wf0l NEJM